Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Lesinurad. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel patent CN106478531B offers high-purity Lesinurad intermediate synthesis with reduced environmental impact and scalable manufacturing for global supply chains.
Patent CN108947919B reveals a safer route avoiding thiophosgene, offering cost reduction in pharmaceutical manufacturing and enhanced supply reliability.
Novel enzymatic N-demethylation route for Lesinurad intermediate. High yield, non-toxic reagents, scalable process for API manufacturing.
Advanced purification method for Lesinurad intermediate achieving over 99% HPLC purity. Cost-effective salt formation technology for reliable pharmaceutical supply chains.
Patent CN103524440A details a safer, thiophosgene-free route for Lesinurad intermediates, offering cost reduction and scalable manufacturing for gout therapeutics.
Patent CN111153862B reveals a novel recrystallization technique for Lesinurad, eliminating critical impurities and ensuring supply chain reliability for API manufacturers.
Patent CN110467580A enables high-purity Lesinurad resolution using quinoline alkaloids, ensuring cost reduction and supply reliability for pharmaceutical intermediates.
Patent CN107098866A reveals cost-effective chemical resolution for Lesinurad enantiomers ensuring high purity and supply chain stability for pharmaceutical manufacturing partners globally.
Patent CN107098866A offers cost-effective chiral resolution for Lesinurad intermediates, ensuring high purity and scalable supply chain solutions for global pharmaceutical manufacturing.
Novel thio-1,2,4-triazole process avoids carcinogens ensuring high purity supply chain reliability for global pharma manufacturing partners
Novel patent CN105906576A offers toxic-free lesinurad intermediate synthesis. High yield 96.30% step ensures cost reduction and supply reliability for pharmaceutical manufacturing.
Novel Lesinurad synthesis patent CN106866560A offers high yield and purity. Ideal for reliable pharmaceutical intermediates supplier seeking cost reduction.
Patent CN105566237A reveals improved Lesinurad synthesis yielding cost reduction and supply chain reliability for pharmaceutical intermediate manufacturing.
Patent CN105263913B details a safer thio-1,2,4-triazole synthesis route offering high purity and cost reduction in API manufacturing for global supply chains.
Patent CN111116501B details a novel catalytic method for synthesizing Lesinurad intermediates, eliminating chlorinated impurities and ensuring scalable API production.
Patent CN107955029A details a high-yield Lesinurad synthesis. Offers cost reduction and supply chain reliability for pharmaceutical manufacturing partners.